Galaxy银河|澳门官网·登录入口

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

RPL41 sensitizes retinoblastoma cells to chemotherapeutic drugs via ATF4 degradation

J Cell Physiol. 2020; 
Wen Geng, Jiaxu Ren, Huimin Shi, Feng Qin, Xiaohe Xu, Sheng Xiao, Yisheng Jiao, Aiyuan Wang
Products/Services Used Details Operation
Peptide Synthesis … China Medical University. 2.2 RPL41 synthesis. The RPL41 peptide (NH 2 ‐MRAKWRKKRMRRLKRKRRKMRQRSK‐OH) was synthesized by GenScript (Nanjing, China), as described previously (A. Wang et al., 2011). The purity … Get A Quote

摘要

Retinoblastoma is the most common intraocular cancer with metastatic potential affecting infants and children. Although chemotherapy is available for retinoblastoma, side effects and drug resistance are frequent. Rpl41, encoding ribosomal protein L41 (RPL41), has been identified as a tumor suppressor gene, and its targeted degradation of activating transcription factor 4 (ATF4) produces an antitumor effect. The goal of the present study is to provide experimental evidence for the clinical application of a small peptide regimen in combination with chemotherapy for the treatment of retinoblastoma and to investigate the mechanism of their combined cytotoxicity. It was observed that treatment with the RPL41 peptide... More

关键词

ATF4, RPL41, carboplatin, drug resistance, retinoblastoma
XML 地图